结直肠癌肝转移的外科治疗现状与进展

肝脏是结直肠癌最常见的远处侵犯器官.手术切除仍是目前唯一有治愈希望的治疗手段.术后患者可以获得25%～39%的5年生存率.但仅有10%～25%的患者确诊时适合手术切除.新疗法如消融术、肝动脉介入化疗、新辅助化疗、靶向治疗等,给不宜手术的患者带来了希望.本文以外科治疗为主对结直肠癌肝转移的治疗做简要综述.

Current therapeutic options and progress for colorectal liver metastases

The liver is a primary target organ of colorectal cancer metastases. Surgical resection is pres-ently the only approach that offers patients a substantial chance of cure. Five-year survival ranges 25% -39%. But by the time of diagnosis, only 10% -25% of patients were considered eligible for surgical directed thera-pies. New therapeutic modalities such as ablation, hepatic arterial infusion chemotherapy, neoadjuvant chem-otherapy and targeted therapy present promise for the future treatment of unresectable liver metastases. These treatments and progress in surgical therapy are reviewed in this article.